Qiagen NV (WBO:QGE2)
€ 40.8 -0.54 (-1.31%) Market Cap: 9.01 Bil Enterprise Value: 9.48 Bil PE Ratio: 137.61 PB Ratio: 2.86 GF Score: 87/100

Qiagen NV at Bank of America Merrill Lynch Global Healthcare Conference Transcript

Sep 13, 2023 / 01:10PM GMT
Release Date Price: €40.29 (+0.33%)
Derik De Bruin
BofA Securities, Research Division - MD of Equity Research

I'm Derik De Bruin, the Senior Life Sciences and Diagnostics Tools Analyst for Bank of America. Welcome to our 2023 Global Healthcare Conference, coming to you live from [London]. Our next company up today is QIAGEN. And with us from QIAGEN, we have Roland Sackers, CFO and Phoebe Loh from IR. Thank you for being here today. I appreciate you making the trip.

Questions & Answers

Derik De Bruin
BofA Securities, Research Division - MD of Equity Research

So do you want to -- I guess, I don't know the -- there's a lot to do, right? I think -- so coming out of 2Q earnings, the macro environment for life sciences is probably more uncertain than it has been in a long time, I would say. So let's do a world win tour of what QIAGEN is seeing, then we'll just go through this and pop it off and we'll hit down some of the specific product lines, and then I'll open up for questions later. So I've been marketing in the last couple of days in London, and #1 question in everyone's mind is China.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot